Trials / Completed
CompletedNCT02058940
Intravenous Exenatide in Patients With Acute Brain Injury
Intravenous Exenatide Infusion in Critically Ill Patients With Acute Brain Injury
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- University of North Carolina, Chapel Hill · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the feasibility of exenatide infusion for the treatment of high blood sugars following acute brain injury.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Exenatide | 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2017-08-01
- Completion
- 2017-08-01
- First posted
- 2014-02-10
- Last updated
- 2018-07-12
- Results posted
- 2018-07-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02058940. Inclusion in this directory is not an endorsement.